Indian drug company to make cheaper generic version of CAB-LA, potentially protecting millions of people in Africa from the virus
An affordable version of a groundbreaking HIV-prevention drug will be made in South Africa for the first time, potentially giving millions of people at risk of HIV infection in Africa access to a two-monthly jab that can almost eliminate their chances of contracting the virus.
The Indian drug company Cipla confirmed that a generic version of the prophylaxis, long-acting cabotegravir (CAB-LA), would be manufactured at its plants in Benoni, near Johannesburg, or Durban.
